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Benzylamide 5’-32P-oligonucleotide derivatives were shown to penetrate into mice organism when administered by various routes: intranasally, per 
OS, intravaginally and per rectum. In all cases, the compounds are rapidly accumulated in blood and guts. Analysis of the radioactive material from 
blood and pancreas revealed intact oligonucleotides. Although concentrations of oligonucleotides in tissues differ considerably by the various 
methods of administration, the efficiency of delivery is sufficient o consider all the routes as being of therapeutic value. Dose effect on the efficiency 
of oligonucleotide penetration into mice suggests the transport o be a saturable process. Application of an oligonucleotide lotion on mice ear helices 
results in reproducible accumulation of radioactivity in the animal tissues. Effectiveness of oligonucleotide delivery into mouse through skin can 
be improved by using electrophoretic procedure. 
Oligonucleotide administration; Oligonucleotide degradation; Drug delivery methods 
1. INTRODUCTION 
The possibility to use oligonucleotide derivatives and 
analogs for regulation of gene expression and suppres- 
sion of viruses multiplication in tissue cultures and the 
data of the first animal tests [ 1,2] have stimulated stud- 
ies on pharmacokinetics of these compounds [3,4]. We 
have found that oligonucleotide derivatives that are in- 
troduced into mice intravenously (i.v.) or intraperitone- 
ally (i.p.) enter all tissues and organs of the animals 
except the brain; they are excreted with urine and sur- 
vive in blood and organs for about 1 h [5], which seems 
sufficient ime for them to affect the target nucleic acids. 
To test alternative methods of administration, we intro- 
duced oligonucleotide derivatives into mice intrana- 
sally, intravaginally, per OS, per rectum, and by different 
methods through the undamaged skin. We have found 
that oligonucleotide derivatives did penetrate into the 
animals although with lower efficiency as compared to 
the i.p. route. They were found in various organs and 
tissues less degraded as compared to the i.p. injected 
compounds. 
2. MATERIALS AND METHODS 
The experiments were performed with the 5’-‘zP labeled oligode- 
oxynucleotide pTGACCCTCTTCCCATT. The S-phosphate of the 
oligonucleotide was conjugated to benzylamine, to protect it from 
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phosphatases [S]. Equal quantities (2 nmol, 2 x lo7 cpm) of the 32P- 
labeled benzylamide oligonucleotide derivative (BzpEJ were intro- 
duced in Balb C mice. BzpE,, in 200 ~1 of physiological salt solution 
was introduced intraperitoneally, intranasally (dropwise into the nose 
holes, total volume 5 pl), per OS (dropwise into the mouth of mice, 50 
pl), intravaginally (by Gilson pipette into the vagina of mice, 10 ~1) 
and rectally (in the distal part of the rectum, 10 ~1). Application onto 
skin was performed as follows: 10 ~1 of the oligonucleotide solution 
containing equal volumes of water, glycerol and Tween 80 was applied 
onto the skin of ear helices of mice. Special attention was paid to 
preventing the mice from licking the solution applied. Electro- 
phoresises through skin of the animals were performed in salt solution. 
An aluminium cathode covered by 1.5 x 1.5 cm Whatman 3MM paper 
which had been soaked with 100~1 of the solution containing 0.15 M 
NaCl and 2 nmol(2 x 10’ cpm) BzpE,, was placed under the stomach 
of the immobilized mouse. An aluminium anode with the paper was 
put on the wet back of the mouse. Electrophoresis was run for 20 min 
at 2 mA. Typically the mice were decapitated 20 min after the admin- 
istration of oligonucleotides. Samples of tissues were weighed and 
counted in a liquid scintillation counter. Blood and pancreas amples 
were homogenized and extracted with an equal volume of phenol. 
Aliquots of the aqueous phases were diluted by 0.5 vol. of glycerol and 
analyzed by gel electrophoresis in 20% PAAG in 7 M urea followed 
by autoradiography. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows distribution of the label among mice 
organs after administration of the oligonucleotide de- 
rivative by different methods. Considerable amount of 
the compounds entered the organism 20 min after they 
had been applied. Intranasal and oral routes provided 
5520% of the delivery efficiency achieved by the i.p. 
injection, i.e. concentration of the oligonucleotides in 
the blood was up to 3 PM in the former versus 15 PM 
in the latter case. These concentrations fit the concen- 
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Fig. 1. Distribution of oligonucleotides in mice organism after administration by different routes. 2 nmol of the [‘*PI-S-benzylphosphoramide 
derivative of the oligonucleotide pTGACCCTCTTCCCATC (BzpE,.J (2.5 Ci/mmol) was administered. 20 min after the administration the mice 
were decapitated, and tissue samples were weighed and counted. L, liver sample; K, kidney sample; B, blood sample; P, pancreas ample; S, spleen 
sample; M, muscle sample. i.p., intraperitoneal injection; i/nasal, intranasal injection; p/oral, per OS injection; ilvag, oligonucleotide was introduced 
into the vagina of mice; plrect, oligonucleotide was introduced into the rectum of mice. 
tration range required for the oligonucleotide deriva- 
tives to affect target viral and cellular nucleic acids 151. 
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Fig. 2. Stability of oligonucleotide derivatives introduced in mice by 
different routes. The experimental conditions were as described in the 
legend to Fig. 1 and section 2. The radioactivity of the blood samples 
(odd-numbered lanes on the gel) and pancreas samples (even-num- 
bered lanes) was analyzed by electrophoresis under denaturing condi- 
tions (20% PAAG, 7 M urea). (1,2) intranasal administration (3,4) 
intravaginal administration; (56) administration per OS; (7,8) i.p. in- 
jection. BzpEn,, position of the initial oligonucleotide derivative; 
BzpN, position of the mononucleotide derivative. 
otides, the concentration of the labeled compound in 
organs was 5-10 times lower than by intranasal and oral 
methods. Application of the aqueous oligonucleotide 
solution onto the skin yielded a small amount of radio- 
activity only in the liver and kidney. However the use 
of the electrophoretic procedure for oligonucleotide de- 
livery through the skin allows to achieve considerable 
radioactivity in all organs (Table I). Application of a 
detergent lotion with oligonucleotide also gave increas- 
ing levels of the label in mouse organs. 
Whatever method of administration was used, the 
oligonucleotide distribution between organs was more- 
or-less the same. It differed considerably from the distri- 
bution of inorganic phosphate when most radioactivity 
remained in the bloodstream even after a few hours post 
injection (data not shown). It means that there is one 
mechanism of transport of the oligonucleotides into or- 
gans: transportation by the bloodstream followed by 
uptake by the cells, which probably includes specific 
oligonucleotide binding to cellular receptors [6]. Re- 
cently we have shown the existence of such cellular re- 
ceptors in some organs of mice and have found that the 
Table I 
Penetration of ~2P-oligonucleotides through skin (~~rng) 
Tissues* L K B P S I M 
Water solution 0.12 0.54 - ~ - - - 
Detergent lotion 0.5 0.5 0.6 0.6 0.25 0.25 0.35 
Electrophoretic 
procedure 2.4 3.5 0.1 2.7 0.2 0.1 2.2 
*The oligonucleotides were administered as described in section 2. L, 
liver; K, kidney; B, blood; P, pancreas: S, spleen; I, intestines; M, 
muscle. 
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Fig. 3. Time course of oligonucleotide accumulation in mice organs after the nasal administration. Experimental conditions were as described in 
the legend to Fig. 1 except for the times. 
number of receptors correlated with the quantity of the 
labeled oligonucleotide internalized by the organs [S]. 
Fig. 2 shows results of electrophoretic analysis of the 
radioactive material from blood and pancreas of mice 
20 min after the administration of the labeled oligonu- 
cleotide derivatives. In all samples undegraded oligonu- 
cleotides are present in reasonable amounts: l&70% of 
total radioactivity. Accumulation of the 32P inorganic 
phosphate in the blood is observed when the oligonucle- 
otides are injected i-p. and per OS. It can be explained 
by the increased activity of macrophages and nucleases 
in the peritoneal cavity and intestines and by the fact 
that the oligonucleotides reach the blood already par- 
tially degraded. It should be noted that formation of 
large amounts of inorganic phosphate without consider- 
able degradation of the remaining oligonucleotide 
points to high phosphoramidase activity, which de- 
taches the benzylamide residue from the oligonucleotide 
and unmasks the 5’-32P phosphate to phosphatase at- 
tack. In the pancreas, the degradation of the oligonucle- 
otides seems somewhat slower than in the blood. This 
obviously means that the pancreatic cells select prefer- 
entially undegraded oligonucleotides from the blood. 
Here we suspect functioning of the oligonucleotide 
binding receptors on pancreatic cells, which can select 
undegraded oligonucleotides. It was found that the 
CD4 receptor binds long oligonucleotides more tightly 
than the short ones, and that the oligonucleotides 
shorter than 5-mer do not bind to the receptor at all [7]. 
A less pronounced degradation of the oligonucleoti- 
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Fig. 4. Dose dependence of efficiency of oligo~ucleotid~ ambulation in mouse organs after nasal ministration. Ex~~mental conditions were 
as described in the legend to Fig. 1 with the exception of the doses. The same volume (5 ~1) of the com~und was introduced each time. 
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des was observed in the case of the intravaginal 
application. 
The intranasal absorption of oligonucleotides is 
rather slow at high oligonucleotide doses (5 nmol per 
animal). Increase in the absorbed radioactivity has been 
observed for up to 2 h after the application (Fig. 4). The 
less efficient uptake at high doses and non-linear de- 
pendence of the absorbed material on the doses applied 
(Fig. 5) may suggest functioning of a saturable uptake 
mechanism. 
The described experiments evidence that the oligonu- 
cleotides can penetrate into mice through the nasal, 
rectal and vaginal mucosa and even through the skin. 
Taking into account the existence of specific nucleic 
acid binding cellular receptors [6,8] we suggest that the 
mechanism of oligonucleotide penetration be transcyto- 
sis through the mucosa cells. This makes one optimistic 
about the prospects of the in vivo use of natural ol- 
igonucleotides. Apparently, topical application of ol- 
igonucleotides to treatment of local lesions caused by 
viruses like the papilloma virus can be envisioned. 
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